GlassScriptPhysician profile
Amy S Thomas
NPI 1821418104
$10,640.34
in general payments reported to CMS, 2019-2025
41 companies · $3,223 in 2025
The $3,223 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $886 · 2022: $2,172 · 2023: $2,170 · 2024: $2,190 · 2025: $3,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,330 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,330.40 |
| Education | $252.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,398.76 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,330.96 | 2021-2025 | Airsupra, Fasenra, Breztri |
| Harmony Biosciences LLC | $1,170.78 | 2022-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $944.52 | 2021-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genzyme Corporation | $584.46 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $544.55 | 2021-2025 | |
| United Therapeutics Corporation | $444.75 | 2021-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $362.59 | 2021-2025 | Zerbaxa, Recarbrio, Keytruda |
| Regeneron Healthcare Solutions, INC. | $315.92 | 2023-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $299.32 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $297.06 | 2021-2025 | Glassia |
| Insmed, INC. | $258.04 | 2022-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $234.46 | 2021-2024 | Xolair |
| Zoll Respicardia, INC. | $229.70 | 2022-2025 | Remede System |
| Lilly USA, LLC | $193.69 | 2025 | Zepbound |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $191.28 | 2021-2025 | |
| La Jolla Pharmaceutical Company | $188.52 | 2022-2023 | Giapreza |
| Inspire Medical Systems, INC. | $168.36 | 2024-2025 | Inspire |
| Pulmonx Corporation | $150.34 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Baxter Healthcare | $145.21 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System, Hillrom - Metaneb System |
| Abbvie INC. | $136.27 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $123.81 | 2025 | Lumryz |
| Mallinckrodt Hospital Products INC. | $104.88 | 2021-2024 | Acthar |
| Philips North America LLC | $103.64 | 2021-2025 | Reusable Vest, Vest Therapy Und |
| Mylan Specialty L.P. | $95.61 | 2021-2024 | Yupelri |
| Viatris Specialty LLC | $76.25 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $75.46 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $72.07 | 2023-2024 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $62.22 | 2025 | Ohtuvayre |
| Amgen INC. | $59.82 | 2022-2023 | Tezspire |
| Axsome Therapeutics, INC. | $56.85 | 2023-2024 | Sunosi |
| Gilead Sciences, INC. | $55.85 | 2022-2023 | |
| Ambu INC. | $24.09 | 2022 | |
| Davol INC. | $23.85 | 2023 | |
| Melinta Therapeutics, LLC | $20.25 | 2024 | Rezzayo, Vabomere |
| Bioxcel Therapeutics, INC. | $19.31 | 2023 | Igalmi |
| Liquidia Technologies, INC. | $17.93 | 2025 | Yutrepia |
| Inogen, INC. | $17.86 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Advanced Respiratory, INC | $15.66 | 2021 | |
| Astellas Pharma US INC | $13.45 | 2021 | |
| Vapotherm INC | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.